Connect with us

Health

Women Still Underrepresented Among Europe’s Inventors Despite Growth in Science Careers

Published

on

Women remain significantly underrepresented among inventors in Europe despite a steady increase in the number of female scientists across the continent, according to a new report from the European Patent Office.

The study found that women accounted for just 13.8 percent of inventors listed in European patent applications in 2022. Although the share has grown from about two percent in the late 1970s and from 13 percent in 2019, progress remains slow.

“Gender gaps still run through the entire innovation system — from the day you sign up to university, to the day you become a team leader or open your own start-up,” Roberta Romano-Götsch, chief sustainability officer and spokesperson at the European Patent Office, said in an interview.

She warned that the pace of change remains far from balanced. “The pace is too slow and far from being balanced,” Romano-Götsch said.

The findings come at a time when the number of women working in science and engineering in the European Union has increased significantly. EU data show that female scientists and engineers rose from 3.4 million in 2008 to 5.2 million in 2014, reaching around 7.9 million in 2024.

In certain research areas, women now make up a large share of the workforce. In medical and health sciences, women represent about 54 percent of all researchers, the highest proportion across research and development fields.

Yet the increase in women working in science has not translated into similar representation in innovation and patenting. Experts often refer to this trend as the “leaky pipeline,” where women are well represented in education and early careers but gradually disappear from senior roles and leadership positions.

See also  Diamond Sensors Offer New Hope for Tracing Breast Cancer Spread

The European Patent Office report said the inventive potential of female researchers is comparable to that of men, suggesting the patent gap cannot be explained by differences in ability or productivity.

Women’s contributions to research and innovation can be seen in several high-profile breakthroughs. Rochelle Niemeijer developed a portable artificial intelligence-based test kit designed to quickly diagnose bacterial infections. Laura van’t Veer and her team created a gene-based test that helps doctors assess the risk of breast cancer returning, allowing many patients to avoid unnecessary chemotherapy. Katalin Karikó, who received the Nobel Prize in Physiology or Medicine in 2023, helped develop modified messenger RNA technology that later became the foundation for COVID-19 vaccines and potential treatments for other diseases.

The report also found that women are more visible in certain fields. In life sciences, including pharmaceuticals, biotechnology and food chemistry, women account for more than 30 percent of inventors, the highest level among all sectors.

Despite these achievements, several barriers continue to affect women’s recognition and advancement. Researchers point to the “Matilda effect,” a term describing how women’s scientific contributions are sometimes overlooked or attributed to male colleagues.

Romano-Götsch said this issue can affect recognition in both academic publications and patent applications. In some cases, women contribute to research but are not credited as inventors when patents are filed.

She said closing these gaps is important not only for fairness but also for innovation and competitiveness. Increasing women’s participation in invention could strengthen research teams, expand the talent pool and improve outcomes across Europe’s scientific and technology sectors.

See also  Portugal Limits Prescriptions for Popular Diabetes and Weight Loss Drugs Amid Misuse Concerns

Health

Genetic Differences May Shape Effectiveness of Popular Weight-Loss Drugs, Study Finds

Published

on

Genetic variations may help explain why some patients respond better than others to widely used weight-loss medications, according to new research that points to the potential for more personalised treatment approaches.

Drugs such as Ozempic, Mounjaro and Zepbound have transformed the treatment of obesity in recent years. These medications belong to a class known as GLP-1 receptor agonists, which mimic a natural hormone that regulates appetite and blood sugar, helping people feel full for longer. Despite their growing use, patient outcomes vary widely, with some individuals losing less than 5 percent of their body weight while others achieve reductions exceeding 20 percent.

The study, conducted by researchers at the 23andMe Research Institute and published in Nature, examined genetic data alongside patient-reported experiences to better understand these differences.

Researchers analysed information from nearly 28,000 participants who had taken GLP-1 medications for a median period of just over eight months. Their findings identified specific genetic variants that appear to influence how individuals respond to these treatments.

One such variation in the GLP1R gene was linked to improved effectiveness. Individuals carrying a particular version of this gene lost an average of 0.76 kilograms more than those without it during the study period. Another variant in the GIPR gene was associated with an increased likelihood of side effects such as nausea and vomiting among patients taking tirzepatide-based drugs, though it did not affect weight loss outcomes.

Noura Abul-Husn, chief medical officer at the research institute, said current approaches to weight management often rely on trial and error. She noted that patients frequently begin treatment without clear expectations about how effective a drug will be or what side effects they might experience.

See also  Study Finds US Doctors Prescribe ADHD Drugs Too Quickly for Young Children

Experts not involved in the study said the findings offer useful insight but should be interpreted with caution. Marie Spreckley of the University of Cambridge said the genetic effects identified are relatively small in clinical terms, especially compared with the typical weight loss of 10 to 15 percent seen in trials of these medications. She added that factors such as dosage, treatment duration, sex and drug type likely play a larger role in determining outcomes.

Still, researchers believe the results could mark a step toward more tailored therapies. Cristóbal Morales, a specialist in metabolic health in Spain, said the ability to predict how patients will respond to treatment through pharmacogenomics could improve both drug selection and safety.

The findings highlight the growing interest in personalised medicine, where treatments are adapted to an individual’s genetic profile, though further studies are needed to confirm how these insights can be applied in clinical practice.

Continue Reading

Health

Seven-Day Meditation Retreat Linked to Measurable Changes in Brain and Body, Study Finds

Published

on

A new study by researchers at the University of California San Diego suggests that a week of intensive meditation and mind-body practices may lead to measurable changes in both brain activity and physical health, highlighting a deeper connection between mental experience and biological function.

The findings, published in Communications Biology, indicate that consistent mental practices can activate biological pathways linked to brain flexibility, immune response, metabolism and natural pain relief. Researchers said the results point to a growing understanding that conscious experience and physical health are closely intertwined and may be used to improve overall well-being.

The study followed 20 healthy adults who participated in a seven-day residential retreat led by neuroscience educator Joe Dispenza. Participants completed about 33 hours of guided meditation along with lectures and group-based activities. Some elements were presented using an “open-label placebo” approach, meaning participants were aware that certain practices were described as placebos, yet previous research suggests such methods can still produce real effects through expectation and group dynamics.

To measure the impact of the retreat, researchers used functional MRI scans and blood tests before and after the programme. The results showed reduced activity in brain regions associated with constant internal thoughts, often described as mental “background noise,” suggesting more efficient brain function.

Blood samples also revealed changes linked to neuroplasticity, with lab-grown neurons exposed to post-retreat plasma showing increased growth and connectivity. Additional findings pointed to improved metabolic flexibility, as well as higher levels of endogenous opioids, the body’s natural painkillers.

Researchers also observed shifts in immune signalling, with both inflammatory and anti-inflammatory responses increasing in what they described as a more balanced and adaptive pattern. Participants reported stronger feelings of unity and altered awareness after the retreat, based on scores from a standard questionnaire used to assess such experiences.

See also  France Prepares Hospitals for Possible Wartime Surge in Military Patients

Hemal H. Patel, who was involved in the research, said the results go beyond simple stress reduction. He noted that combining multiple mind-body techniques appeared to influence several biological systems at once, with measurable effects in both brain scans and blood chemistry.

The study also found that patterns of brain connectivity observed after the retreat resembled those previously associated with psychedelic substances, suggesting that similar states may be achieved through meditation alone.

Despite the findings, researchers cautioned that the study was limited by its small sample size and lack of a control group. They said further research is needed to determine whether the same effects would be seen in larger and more diverse populations.

Alex Jinich-Diamant said the results provide rare biological evidence linking mental states to physical changes in the body. He added that the research offers new insight into how attention, belief and structured practices may leave measurable effects on human biology, opening potential pathways for improving health through non-pharmacological methods.

Continue Reading

Health

Uzbekistan to Launch Nationwide State Medical Insurance System in 2026

Published

on

Uzbekistan will begin introducing a nationwide state medical insurance system from 2026, part of a broader overhaul of the country’s healthcare financing and service delivery. The reform will introduce digital referrals, a national health insurance fund, and a guaranteed package of essential medical services funded through the state budget. Officials say the changes aim to improve efficiency, expand access, and reduce informal payments.

“State health insurance is a social protection system designed to guarantee access to quality healthcare services,” said Zokhid Ermatov, executive director of the State Health Insurance Fund.

Discussions about state medical insurance in Uzbekistan began in 2017, but implementing such a system required years of preparation. The State Health Insurance Fund was formally established in December 2020, and pilot programmes launched in the Syrdarya region in 2021 tested new financing mechanisms, regulatory frameworks, and digital health systems. In November 2025, the Cabinet of Ministers approved regulations governing how medical care funded through the state budget will be provided in public and private medical institutions, with the rules set to come into force on January 1, 2026.

At the centre of the new model is stronger primary healthcare. Patients will first visit their assigned family clinic, where doctors provide consultations, prescribe tests, and determine whether specialist care is needed. If necessary, patients will receive an electronic referral to hospitals or specialists. Emergency and urgent care will remain available without referrals.

The reform introduces a patient-centred financing model, where healthcare providers are paid by the State Health Insurance Fund based on services delivered. Primary healthcare will be funded through capitation payments, while hospital treatment will follow case-based payments, a structure designed to improve efficiency and treatment outcomes.

See also  Chikungunya Outbreak Spreads Rapidly in Southern China, Thousands Infected

A fully digital referral system will allow patients to choose hospitals from a list of institutions contracted with the State Health Insurance Fund using a government portal or mobile app. Referrals will remain valid for 60 days, and waiting lists and hospitalisations will be managed through a unified electronic health information system.

The insurance system guarantees essential healthcare services, including family doctor consultations, diagnostic tests, outpatient treatment, preventive screening, some medicines, hospital care, and certain rehabilitation services. Patients will not be charged additional fees for services included in the approved package.

Funding for the program will come primarily from the state budget, ensuring citizens do not pay direct insurance contributions. Priority access will be given to socially vulnerable groups, including children with disabilities, orphans, pensioners, pregnant women, unemployed citizens, and low-income families. The State Health Insurance Fund will allocate resources across regions to strengthen medical services and reduce inequalities.

International organisations have praised Uzbekistan’s approach, noting that general tax financing and universal coverage can improve financial protection and ensure predictable healthcare funding. Jessika Yin, Health Policy Adviser at the World Health Organization in Uzbekistan, said the reforms align with global trends toward universal health coverage.

If implemented successfully, Uzbekistan’s state medical insurance system could represent a major step toward universal healthcare, ensuring that people receive care without facing financial hardship.

Continue Reading

Trending